Lessee, Operating Lease, Liability, to be Paid, Year Two of Keros Therapeutics, Inc. from 31 Dec 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
Keros Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two in USD history and change rate from 31 Dec 2020 to 31 Dec 2025.
  • Keros Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Two for the quarter ending 31 Dec 2025 was $4,125,000, a 3.1% increase year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year Two, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year Two, YoY Quarterly Change (%)

Keros Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, to be Paid, Year Two (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $4,125,000 +$123,000 +3.1% 31 Dec 2025 10-K 04 Mar 2026 2025 FY
Q4 2024 $4,002,000 +$1,498,000 +60% 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q3 2024 $4,002,000 +$1,498,000 +60% 30 Sep 2024 10-Q 06 Nov 2024 2024 Q3
Q4 2023 $2,504,000 +$302,000 +14% 31 Dec 2023 10-K 28 Feb 2024 2023 FY
Q3 2023 $2,504,000 30 Sep 2023 10-Q 06 Nov 2023 2023 Q3
Q2 2023 $2,542,000 30 Jun 2023 10-Q 07 Aug 2023 2023 Q2
Q1 2023 $2,523,000 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $2,202,000 +$1,968,000 +841% 31 Dec 2022 10-K 03 Mar 2023 2022 FY
Q4 2021 $234,000 -$263,000 -53% 31 Dec 2021 10-K 09 Mar 2022 2021 FY
Q3 2021 $233,000 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q4 2020 $497,000 31 Dec 2020 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.